Triple Negative Breast Neoplasms

Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Also Known As:

ER-Negative PR-Negative HER2-Negative Breast Cancer; ER-Negative PR-Negative HER2-Negative Breast Neoplasms; Triple Negative Breast Cancer; Triple-Negative Breast Cancer; Triple-Negative Breast Neoplasm; Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer; ER Negative PR Negative HER2 Negative Breast Neoplasms; Triple Negative Breast Neoplasm; Triple-Negative Breast Cancers; Triple-Negative Breast Neoplasms

Networked: 11230 relevant articles (668 outcomes, 1446 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Breast Neoplasms (Breast Cancer)
3.	Neoplasm Metastasis (Metastasis)
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
5.	Pathologic Complete Response

Experts

1.	Shao, Zhi-Ming: 48 articles (10/2022 - 05/2009)
2.	Xu, Binghe: 39 articles (02/2022 - 01/2013)
3.	Ma, Fei: 39 articles (01/2022 - 02/2010)
4.	Tolaney, Sara M: 38 articles (12/2022 - 09/2013)
5.	Pusztai, Lajos: 36 articles (10/2022 - 03/2008)
6.	Rugo, Hope S: 35 articles (09/2022 - 01/2010)
7.	Loibl, Sibylle: 34 articles (06/2022 - 06/2014)
8.	Winer, Eric P: 34 articles (01/2022 - 12/2008)
9.	Perou, Charles M: 33 articles (06/2022 - 12/2008)
10.	Xie, Xiaoming: 33 articles (03/2022 - 12/2012)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Triple Negative Breast Neoplasms:

1.	Immune Checkpoint InhibitorsIBA 10/01/2021 - "Recent studies have proven efficacy of immune checkpoint inhibition (ICI) in treatment of triple negative breast cancer (TNBC). " 01/01/2022 - "Immune checkpoint inhibitors had a great effect in triple-negative breast cancer (TNBC); however, they benefited only a subset of patients, underscoring the need to co-target alternative pathways and select optimal patients. " 01/01/2021 - "Immune checkpoint blockade (ICB) has been approved for the treatment of triple-negative breast cancer (TNBC), since it significantly improved the progression-free survival (PFS). " 06/01/2022 - "Immune checkpoint inhibitor (ICI) monotherapy appears to be effective in a small cohort of patients with metastatic triple negative breast cancer (mTNBC). " 06/16/2023 - "Although immune checkpoint inhibitors improved the clinical outcomes of advanced triple negative breast cancer (TBNC) patients, the response rate remains relatively low. "
2.	Paclitaxel (Taxol)FDA LinkGeneric 10/01/2014 - "RES, both alone and in combination with paclitaxel, may be useful in the treatment of paclitaxel-sensitive and paclitaxel-resistant triple-negative breast cancer cells." 10/30/2023 - "Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer." 09/08/2023 - "Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer." 07/20/2015 - "Weekly paclitaxel improved DFS and OS (HR, 0.69; P = .010 and HR, 0.69; P = .019, respectively) in triple-negative breast cancer. " 01/01/2022 - "This study aims to investigate the effect of Radix Tetrastigma extracts (RTEs) on Taxol-induced autophagy and the chemosensitivity against drug resistance in triple-negative breast cancer (TNBC). "
3.	Carboplatin (JM8)FDA LinkGeneric 01/01/2016 - "Dual HER2 blockade and the introduction of carboplatin for triple negative breast cancers (TNBC) emerged by December 2013 and have improved pathological complete response (pCR) rates. " 05/24/2016 - "This study was to investigate the prognostic role of Ki-67 in further classification of triple negative breast cancer (TNBC), and to test whether high expression level of Ki67 can predict benefit from carboplatin. " 11/01/2023 - "Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial." 05/09/2023 - "Publisher Correction: Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft." 01/01/2023 - "Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft."
4.	atezolizumabIBA 11/01/2020 - "Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?" 01/01/2020 - "Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)." 01/01/2020 - "Herein, we review the pharmacodynamic and pharmacokinetic properties of atezolizumab, its safety and efficacy data from early clinical trials and summarize data from Phase III IMpassion130 trial, prompting FDA and EMA approval of atezolizumab in metastatic triple-negative breast cancer. " 12/27/2019 - "Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)." 08/01/2023 - "Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1."
5.	Cisplatin (Platino)FDA LinkGeneric 07/01/2020 - "Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance." 03/01/2010 - "Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer." 01/01/2022 - "In our label-free, high-throughput, quantitative LC-MS/MS-based proteomic studies of MDA-MB-231, human, triple-negative breast cancer cells, treated with electrical pulses (EP) and cisplatin (CsP), we identified a number of HSPs, such as HSP90AA1, and others to be significantly downregulated in EP + CsP, compared to CsP alone. " 01/01/2017 - "The goal of this study was to determine whether AuNPs contribute to improving the treatment response when combined with fractionated cisplatin-based chemoradiation in both in vitro and in vivo models of triple-negative breast cancer (MDA-MB-231Luc+). " 01/20/2015 - "In this study, we investigated the effects of CXCR4 gene silencing on cisplatin chemosensitivity in human triple-negative breast cancer cell lines. "
6.	130-nm albumin-bound paclitaxelIBA 08/01/2020 - "Nab-paclitaxel may have greater benefits in patients with triple-negative breast cancer. " 06/01/2020 - "Triple-negative breast cancer (TNBC) showed the highest estimates of ORR [overall population: 49.7%, 95% confidence interval (CI): 33.9-65.5%; PD-L1 positive population: 55.8%, 95% CI: 42.9-68.8%] and DCR (overall population: 67.5%, 95% CI: 38.6-96.4%; PD-L1 positive population: 83.4%, 95% CI: 72.2-94.5%) post-anti-PD-L1 plus nab-paclitaxel treatment. " 11/01/2016 - "In combination with nab-paclitaxel, confirmed response rates were 46% in a PD-L1-unselected population in the first-line metastatic triple-negative breast cancer setting. " 11/01/2016 - "Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives." 01/01/2020 - "Benefits of combining anti-PD-L1 therapy with nab-paclitaxel in patients with advanced triple-negative breast cancer (TNBC) have been reported. "
7.	Doxorubicin (Adriamycin)FDA LinkGeneric 12/10/2020 - "Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo." 07/20/2023 - "This study aimed to investigate metabolic changes following the acquisition of resistance to doxorubicin in the triple-negative breast cancer (TNBC) cell line MDA-MB-231. " 02/10/2023 - "In our study, we have evaluated the expression of the main lymphangiogenic receptor VEGFR3 in two triple-negative breast cancer in vitro models, resistant or not to doxorubicin treatment. " 01/01/2023 - "In this study, the canine triple negative breast cancer cell line CMT-7364 was induced to develop multidrug resistance using doxorubicin by high-dose drug pulse method. " 01/01/2023 - "A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer."
8.	PlatinumIBA 09/01/2015 - "However, comparison with platinum monotherapy trials suggests that PEI/PI might be a more effective treatment for patients with triple-negative breast cancer." 10/15/2022 - "Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis." 04/01/2020 - "To compare the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced triple-negative breast cancer (TNBC) and analyze the relationship between their efficacy and BRCA gene status. " 04/01/2020 - "Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing." 09/27/2022 - "Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial."
9.	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/28/2022 - "Poly ADP-ribose polymerase inhibitor (PARPi) treatment is effective in triple-negative breast cancer (TNBC) with BRCA mutation. " 11/01/2019 - "Poly ADP-ribose polymerase inhibitors (PARPi) have shown promising therapeutic efficacy in triple-negative breast cancer (TNBC) patients. " 01/01/2014 - "Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness." 01/01/2021 - "Preclinical studies have evidenced that triple-negative breast cancer (TNBC) cell lines are more sensitive to poly (ADP-ribose) polymerase inhibitors. " 10/01/2010 - "This hypothesis has borne out in both preclinical models and in clinical trials testing PARP inhibitors in both BRCA-deficient and triple-negative breast cancer. "
10.	Biomarkers (Surrogate Marker)IBA 08/01/2018 - "The identification of biomarkers related to the prognosis of triple-negative breast cancer (TNBC) is critically important for improved understanding of the biology that drives TNBC progression. " 01/01/2023 - "PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis." 01/01/2021 - "The purpose of our research was to compare triple negative breast cancer to non-triple negative breast cancer to identify key epidemiologic factors that might lead to improved basic science directives for biomarkers, treatments, and classification. " 11/25/2019 - "Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification." 01/01/2023 - "Our study indicates that targeting MAP7D3 could be a promising therapeutic strategy for addressing the progression of TNBC, and MAP7D3 may serve as a novel predictive biomarker for the survival outcomes of triple-negative breast cancer."

Therapies and Procedures

1.	Therapeutics 10/01/2022 - "Importantly, PDC strategy exerts potent therapeutic efficacy against PTEN-loss metastatic triple-negative breast cancer, the highly aggressive and heterogenous nature of which remains a challenge conventional targeted therapies need to overcome. " 11/01/2021 - "SIGNIFICANCE: These findings suggest that triple-negative breast cancer is highly reliant on OXPHOS and that inhibiting OXPHOS may be a novel approach to enhance efficacy of several targeted therapies." 01/01/2021 - "Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subtyping may result in improved diagnostic precision and targeted therapies. " 05/01/2022 - "Time to first subsequent therapy or death (TFST) from date of mBC diagnosis and start of first-line treatment for mBC and overall survival (OS) from date of mBC diagnosis were investigated according to BRCA status (BRCAm, BRCA wild type [BRCAwt] or unknown BRCA [BRCAu]) and HR status (positive/triple negative breast cancer [TNBC]). " 02/01/2017 - "The outcome of triple negative breast cancer is still poor and requires improvement with better therapy options. "
2.	Drug Therapy (Chemotherapy) 12/01/2022 - "Although chemotherapy, the most widely used systemic treatment in triple-negative breast cancer (TNBC), markedly improved the patients' outcome, chemoresistance always occurs. " 01/01/2022 - "Triple negative breast cancer (TNBC) is challenging for effective remission due to its very aggressive, extremely metastatic and resistant to conventional chemotherapy. " 02/01/2010 - "Ongoing clinical studies of newer targeted agents, along with optimal chemotherapy, portend an improved clinical outcome for patients with aggressive basal-like/triple-negative breast cancer in the future." 01/01/2022 - "Checkpoint inhibition in combination with chemotherapy has proven to be effective for the treatment of a subset of advanced triple-negative breast cancer in the first-line setting. " 08/11/2021 - "For this reason, P-gp chemoresistance evaluation, established before or during chemotherapy, can be very relevant in order to optimize the efficacy of treatments, particularly for aggressive tumoral subtypes such as triple-negative breast cancer (TNBC). "
3.	Neoadjuvant Therapy 08/01/2023 - "Tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in relation to pathological complete remission to neoadjuvant therapy and prognosis in triple negative breast cancer." 01/01/2023 - "Achieving a pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) is associated with improved patient outcomes in triple-negative breast cancer (TNBC). " 01/01/2020 - "When clinical complete remission shown by contrast-enhanced magnetic resonance imaging was reached in the course of neoadjuvant chemotherapy against basal-like triple-negative breast cancer, the neoadjuvant chemotherapy period was shortened in 14 (64%) of 22 good responders. " 01/01/2019 - "Achieving pathological complete remission because of neoadjuvant therapy has been correlated with long-term clinical benefit, particularly in HER2-positive and triple-negative breast cancer. " 01/01/2016 - "The mortality of patients with locally advanced triple-negative breast cancer (TNBC) is high, and pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) is associated with improved prognosis. "
4.	Immunotherapy 01/01/2022 - "Immunotherapy is the most promising treatment in triple-negative breast cancer (TNBC), and its efficiency is largely dependent on the intra-tumoral immune cells infiltrations. " 01/01/2022 - "In triple-negative breast cancer (TNBC), PDL1/PD1-directed immunotherapy is effective in less than 20% of patients. " 11/26/2020 - "With improved understanding of the immunogenicity of triple-negative breast cancer (TNBC), immunotherapy has emerged as a promising candidate to treat this lethal disease owing to the lack of specific targets and effective treatments. " 12/01/2022 - "Immunotherapy is a promising treatment for triple-negative breast cancer (TNBC), but patients relapse, highlighting the need to understand the mechanisms of resistance. " 01/01/2023 - "Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer."
5.	Adjuvant Chemotherapy 10/01/2017 - "Triple-negative breast cancers (TNBCs) are considered as associated with poor outcome, but prognosis of subcentimetric, node-negative disease remains controversial and evidence that adjuvant chemotherapy (CT) is effective in these small tumours remains limited. " 07/01/2019 - "Efficacy of Neoadjuvant Versus Adjuvant Chemotherapy in Hispanic/Latino (H/L) Women With Local or Locally Advanced Triple-negative Breast Cancer (TNBC)." 10/01/2016 - "[A Multivariate Analysis of the Efficacy of Adjuvant Chemotherapy in Triple-Negative Breast Cancer]." 06/01/2013 - "We investigated the impact of BRCA1-methylation status on the efficacy of adjuvant chemotherapy in patients with triple-negative breast cancer or with non-triple-negative breast cancer. " 07/31/2023 - "This study analyzed the trend and prognostic role of postoperative adjuvant chemotherapy (POCT) in patients with stage I triple-negative breast cancer (TNBC) aged more than 65 years. "